BioCentury | Jan 14, 2016
Distillery Therapeutics

Therapeutics: Cholesteryl ester transfer protein (CETP)

...atherosclerosis. Chemical synthesis and in vitro testing of triphenylethanamine analogs identified a lead compound ( BMS-795311...
...decreased CETP activity in plasma with comparable potency to the CETP inhibitor torcetrapib. In rats, BMS-795311...
...testing BMS-795311 in animal models of atherosclerosis. Bristol-Myers Squibb Co. and Simcere Pharmaceutical Group have BMS-795311...
BioCentury | Jun 24, 2013
Company News

Simcere, Bristol-Myers deal

...2011, Bristol-Myers granted Simcere exclusive rights in China to develop and commercialize preclinical cardiovascular compound BMS-795311...
BioCentury | Dec 19, 2011
Company News

Simcere, Bristol-Myers deal

...Bristol-Myers granted Simcere exclusive rights in China to develop and commercialize preclinical cardiovascular compound BMS-795311. Bristol-Myers...
BioCentury | Dec 19, 2011
Finance

Highlights of weekly biotech stock moves

...$0.25 to $7.20 last week after receiving exclusive rights in China to preclinical cardiovascular compound BMS-795311...
BioCentury | Dec 15, 2011
Company News

BMS, Simcere in deal for CETP inhibitor

...rights in China to develop and commercialize preclinical cardiovascular compound BMS-795311. Bristol-Myers retains rights elsewhere. BMS-795311...
Items per page:
1 - 5 of 5